Replacement therapy with recombinant factor IX. A multicentre evaluation of current dosing practices in Italy.

Abstract

BACKGROUND: The in vivo recovery of recombinant factor IX (rFIX) is reported to be lower than that of plasma-derived products, with potential clinical implications for dosing. In clinical practice, a conversion (augmentation) factor is suggested to calculate the necessary doses of rFIX. The aim of this study was to assess the range of values for the conversion factor in usual clinical practice in Italy. MATERIALS AND METHODS: The study was …

Authors

Rocca A; Pizzinelli S; Oliovecchio E; Santagostino E; Rocino A; Iorio A

Journal

Blood Transfusion, Vol. 9, No. 1, pp. 60–69

Publication Date

1 2011

DOI

10.2450/2010.0011-10

ISSN

1723-2007

Associated Experts

Alfonso Iorio

Professor, Faculty of Health Sciences

Visit profile

Labels